Also indexed as: Depigmentation
Vitiligo is a type of skin discoloration characterized by progressively widening areas of
depigmented (very white) skin. The depigmentation that occurs with this condition is
associated with the local destruction of melanocytes, the cells that produce the pigment that
darkens the skin, called melanin. Vitiligo affects 1–4% of the world’s
population.1
What are the symptoms of vitiligo? Symptoms of vitiligo
include decreased or absent pigmentation in localized or diffuse areas of the skin. Hair in
these areas is typically white, and the skin tends to sunburn more easily.
How is it treated? Conventional treatment includes cosmetic
creams and tanning solutions, topical cortisone or related drugs, oral and topical psoralens
(drugs that increase the skin’s sensitivity to light) with ultraviolet A irradiation
(PUVA), and, rarely, skin transplants. Treatment may also involve the management of any
underlying medical condition, such as Vogt-Koyanagi-Harada syndrome, scleroderma,
melanoma-associated leukoderma, chronic mucocutaneous candidiasis, and autoimmune disorders
(including Grave’s disease, diabetes mellitus, pernicious anemia, and Addison’s
disease).
Nutritional supplements that may be helpful: Supplementation
with the amino acid L-phenylalanine (LPA) may have
value when combined with ultraviolet (UVA) light
therapy. Several clinical trials, including one double-blind trial, indicated that LPA (50
mg per 2.2 pounds of body weight per day—3,500 mg per day for a 154-pound
person—or less) increased the extent of repigmentation induced by UVA therapy. LPA alone
also produced a more modest repigmentation in some people.2 A study of vitiligo in
children reported that LPA plus UVA was an effective treatment in a majority of the
children.3
A group of Spanish doctors reported on their experience using LPA over a six-year period.
Some of the 171 people with vitiligo received LPA (50 or 100 mg per 2.2 pounds body weight per
day) for up to three years. Between April and October of each year, participants also applied
a 10% LPA gel, prior to exposing their skin to the sun for 30 minutes. Some improvement was
seen in 83% of participants, and the results were rated as good in 57% (75% improvement or
better).4
A clinical report describes the use of vitamin supplements in the treatment of
vitiligo.5 Folic acid and/or vitamin B12 and vitamin C
levels were abnormally low in most of the 15 people studied. Supplementation with large
amounts of folic acid (1–10 mg per day), along with vitamin C (1 gram per day) and
intramuscular vitamin B12 injections (1,000 mcg every two weeks), produced marked
repigmentation in eight people. These improvements became apparent after three months, but
complete repigmentation required one to two years of continuous supplementation. In another
study of people with vitiligo, oral supplementation with folic acid (10 mg per day) and
vitamin B12 (2,000 mcg per day), combined with sun exposure, resulted in some repigmentation
after three to six months in about half of the participants.6 This combined regimen
was more effective than either vitamin supplementation or sun exposure alone.
When used topically in combination with sun exposure, a pharmaceutical form of vitamin D, called calcipotriol, may be effective in stimulating
repigmentation in children with vitiligo. In a preliminary study, children applied a cream
containing calcipotriol daily and exposed themselves to sunlight for 10–15 minutes the
following morning.7 After 11 months, marked to complete repigmentation occurred in
55% of the children, moderate repigmentation occurred in 22%, and little or no improvement was
seen in 22%. None of the children developed new areas of vitiligo. The first evidence of
repigmentation occurred within 6 to 12 weeks in the majority of the children. All participants
tolerated the cream well, with approximately 17% complaining of mild, transient skin
irritation. Calcipotriol is a prescription medication to be used only under the supervision of
a doctor. It is not known whether vitamin D as a dietary supplement has any effect on
vitiligo.
In one early report, lack of stomach acid (achlorhydria) was associated with vitiligo.
Supplementation with dilute hydrochloric acid after meals resulted in gradual repigmentation
of the skin (after one year or more).8 Hydrochloric acid, or its more modern
counterpart betaine HCl, should be taken only under the
supervision of a doctor.
Another early report described the use of PABA
(para-aminobenzoic acid)—a compound commonly found in B-complex vitamins—for vitiligo. Consistent use of
100 mg of PABA three or four times per day, along with an injectable form of PABA and a
variety of hormones tailored to individual needs, resulted, in many cases, in repigmentation
of areas affected by vitiligo.9
Are there any side effects or interactions? Refer to the individual supplement for
information about any side effects or interactions.
Herbs that may be helpful: An extract from khella (Ammi
visnaga) may be useful in repigmenting the skin of people with vitiligo. Khellin, the
active constituent, appears to work like psoralen drugs—it stimulates repigmentation of
the skin by increasing sensitivity of remaining melanocytes to sunlight. Studies have used
120–160 mg of khellin per day.10
In preliminary trial, Picrorhiza, in combination with
the drug methoxsalen and sun exposure, was reported to hasten recovery in people with vitiligo
compared with use of methoxsalen and sun exposure alone.11 Between 400 and 1,500 mg
of powdered, encapsulated picrorhiza per day has been used in a variety of studies.
Are there any side effects or interactions? Refer to the individual herb for
information about any side effects or interactions.
Other integrative approaches that may be helpful: People with
vitiligo have occasionally improved using hypnosis
along with other treatments.12
References:
1. Ortonne JP, Bose SK. Vitiligo: where do we stand? Pigment Cell
Res 1993;6:61–72.
2. Siddiqui AH, Stolk LM, Bhaggoe R, et al. L-phenylalanine and UVA
irradiation in the treatment of vitiligo. Dermatology 1994;188:215–8.
3. Schulpis CH, Antoniou C, Michas T, Strarigos J. Phenylalanine plus
ultraviolet light: preliminary report of a promising treatment for childhood vitiligo.
Pediatr Dermatol 1989;6:332–5.
4. Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical
phenylalanine: 6 years of experience. Arch Dermatol 1999;135:216–7.
5. Montes LF, Diaz ML, Lajous J, Garcia NJ. Folic acid and vitamin B12 in
vitiligo: a nutritional approach. Cutis 1992;50:39–42.
6. Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with
vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol
1997;77:460–2.
7. Parsad D, Saini R, Nagpal R. Calcipotriol in vitiligo: A preliminary
study. Pediatr Dermatol 1999;16:317–20.
8. Francis HW. Achlorhydria as an etiological factor in vitiligo, with
report of four cases. Nebraska State Med J 1931;16(1):25–6.
9. Sieve BF. Further investigations in the treatment of vitiligo.
Virginia Med Monthly 1945;Jan:6–17.
10. Abdel-Fattah, Aboul-Enein MN, Wassel GM, El-Menshawi BS. An approach
to the treatment of vitiligo by khellin. Dermatologica 1982;165:136–40.
11. Bedi KL, Zutshi U, Chopra CL, Amla V. Picrorhiza kurroa, an
Ayurvedic herb, may potentiate photochemotherapy in vitiligo. J Ethnopharmacol
1989;27:347–52.
12. Shenefelt PD. Hypnosis in dermatology. Arch Dermatol
2000;136:393–9.
Copyright © 2002 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Learn more about Healthnotes, the company.
Learn more about the authors of Healthnotes.
The information presented in Healthnotes is for informational
purposes only. It is based on scientific studies (human, animal, or in vitro),
clinical experience, or traditional usage as cited in each article. The results reported may
not necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over-the-counter medication is also available. Consult your doctor,
practitioner, and/or pharmacist for any health problem and before using any supplements or
before making any changes in prescribed medications. Information expires December 2003.
|